非ステロイド性抗炎症薬市場：疾患別、薬剤別、投与経路別、流通チャネル別-2025-2030年の世界予測

非ステロイド性抗炎症薬市場は、2023年に217億1,000万米ドルと評価され、2024年には232億4,000万米ドルに達すると予測され、CAGR 7.53％で成長し、2030年には361億米ドルになると予測されています。

非ステロイド性抗炎症薬（非ステロイド性抗炎症薬）は、シクロオキシゲナーゼ酵素を阻害することにより、痛みを和らげ、炎症を抑え、熱を下げるために使用される薬の一種です。これらの薬剤は、関節炎、筋肉痛、頭痛などの症状管理に不可欠です。NSAIDsの適用範囲は、軽度から中等度の痛みを和らげるための市販薬と、慢性炎症性疾患のための処方薬に及ぶ。最終用途には主にヘルスケア施設、小売薬局、個人ユーザーが含まれます。NSAID市場に影響を与える主な成長要因としては、慢性疼痛疾患の有病率の増加、人口の高齢化、疼痛管理オプションに対する意識の高まりなどが挙げられます。さらに、消化器系の副作用を最小限に抑え、NSAIDsの有効性を高める製剤の進歩は、注目に値する市場機会をもたらしています。非ステロイド性抗炎症薬の外用剤形や併用療法などの革新は、ビジネスの成長と拡大のための潜在的な手段となります。

しかし、NSAIDsには消化管出血や心血管系リスクなどの副作用があるため、使用量が抑制され、規制当局の監視が厳しくなるなど、市場の成長には限界があります。さらに、炎症性疾患に対する生物学的製剤のような代替療法の出現は、NSAIDsに競合をもたらします。NSAIDsの市場機会を生かそうとする企業にとっては、消化管安全性プロファイルを改善した製剤や選択的COX-2阻害剤など、より安全性の高い製剤の開拓に注力することが有利に働く可能性があります。非ステロイド性抗炎症薬（NSAID）療法を個人の遺伝的プロファイルに合わせて調整する個別化医療（personalized medicine）アプローチの研究を拡大することも、競争優位性をもたらす可能性があります。非ステロイド性抗炎症薬市場の競争は激しく、大手製薬企業は製品の差別化と市場浸透戦略に多額の投資を行っています。成長の勢いを維持するためには、規制経路と患者のコンプライアンス・パターンを継続的に監視することが重要です。製品イノベーションのための戦略的パートナーシップや共同研究への参加は有益です。結論として、非ステロイド性抗炎症薬（NSAIDs）は疼痛・炎症管理の要であり続ける一方で、安全性への懸念に対処し、新たなドラッグデリバリーシステムを模索することが、市場の潜在力を活用する上で最も重要です。

市場力学：急速に進化する非ステロイド性抗炎症薬市場における主要市場インサイトの解明

非ステロイド性抗炎症薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疼痛症例の増加と炎症症例の急増
  • 老人人口の増加と非ステロイド性抗炎症薬の使用に関する意識の高まり
  • オピオイドよりもNSAIDを好む人の増加
• 市場抑制要因
  • 非ステロイド性抗炎症薬使用に伴う副作用
• 市場機会
  • 政府による迅速な承認と政府イニシアチブの増加
  • 新たな技術、研究開発活動、新薬の上市
• 市場の課題
  • 臨床試験中の薬剤の失敗

ポーターの5つの力：非ステロイド性抗炎症薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：非ステロイド性抗炎症薬市場における外部からの影響の把握

外部マクロ環境要因は、非ステロイド性抗炎症薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析非ステロイド性抗炎症薬市場における競合情勢の把握

非ステロイド性抗炎症薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス非ステロイド性抗炎症薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、非ステロイド性抗炎症薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨非ステロイド性抗炎症薬市場における成功への道筋を描く

非ステロイド性抗炎症薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疼痛症例の増加と炎症症例の急増
    • 高齢者人口の増加と非ステロイド性抗炎症薬の使用に関する意識の高まり
    • オピオイドよりもNSAIDを好む人が増えている
  • 抑制要因
    • 非ステロイド性抗炎症薬の使用に伴う副作用
  • 機会
    • 政府による迅速な権限承認と政府主導の取り組みの増加
    • 新興技術、研究開発活動、新薬の発売
  • 課題
    • 臨床試験中の薬剤の失敗
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 非ステロイド性抗炎症薬市場：疾患適応症別

• 関節炎
• 片頭痛
• 眼科疾患

第7章 非ステロイド性抗炎症薬市場薬物別

• 市販薬
  • アスピリン（バファリン、バイエル、エクセドリン）
  • イブプロフェン（アドビル、モトリン、ヌプリン）
  • ケトプロフェン（アクトロン、オルディス）
  • ナプロキセン（アレーブ）
• 処方箋
  • デイプロ
  • インドシン
  • ロディン
  • ナプロシン
  • リラフェン
  • ヴィモヴォ
  • ボルタレン

第8章 非ステロイド性抗炎症薬市場：投与経路別

• オーラル
• 非経口

第9章 非ステロイド性抗炎症薬市場：流通チャネル別

• ドラッグストア
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの非ステロイド性抗炎症薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の非ステロイド性抗炎症薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの非ステロイド性抗炎症薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Apotex Inc.
• Assertio Therapeutics, Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Iroko Pharmaceuticals Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Perrigo Company PLC
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN (BUFFERIN, BAYER, & EXCEDRIN), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN (ADVIL, MOTRIN, NUPRIN), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN (ACTRON, ORUDIS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN (ALEVE), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DAYPRO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDOCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LODINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROSYN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELAFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VIMOVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VOLTAREN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 197. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 221. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 227. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRU

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 21.71 billion in 2023, expected to reach USD 23.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 36.10 billion by 2030.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are a class of medications used to alleviate pain, decrease inflammation, and reduce fever by inhibiting cyclooxygenase enzymes. These drugs are essential in managing conditions like arthritis, muscular pain, and headaches. The application scope of NSAIDs spans over-the-counter use for mild to moderate pain relief and prescription use for chronic inflammatory diseases. The end-use scope primarily includes healthcare facilities, retail pharmacies, and individual users. Key growth factors influencing the NSAID market include increasing prevalence of chronic pain conditions, an aging population, and heightened awareness of pain management options. Moreover, advancements in drug formulations that minimize gastrointestinal side effects and elevate the efficacy of NSAIDs present noteworthy market opportunities. Innovations like topical NSAID forms and combination therapies serve as potential avenues for business growth and expansion.

However, market growth faces limitations, notably due to the side effects of NSAIDs, such as gastrointestinal bleeding and cardiovascular risks, which can deter usage and lead to stringent regulatory scrutiny. Additionally, the advent of alternative therapies like biologics for inflammatory conditions poses competition to NSAIDs. For companies aiming to capitalize on NSAID market opportunities, focusing on developing safer formulations, such as those with improved gastrointestinal safety profiles or selective COX-2 inhibitors, can be advantageous. Expanding research into personalized medicine approaches that tailor NSAID therapies to individual genetic profiles can also offer a competitive edge. The nature of the NSAID market is highly competitive, with major pharmaceutical companies investing heavily in product differentiation and market penetration strategies. Continued surveillance of regulatory pathways and patient compliance patterns is crucial for maintaining growth momentum. Engaging in strategic partnerships and collaborations for product innovation can be instrumental. In conclusion, while NSAIDs remain a cornerstone in pain and inflammation management, addressing safety concerns and exploring novel drug-delivery systems will be paramount in harnessing market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-steroidal Anti-inflammatory Drugs Market

The Non-steroidal Anti-inflammatory Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in chronic pain cases and surge in inflammation cases
  • Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
  • Increasing preference of people for nsaids over opioids
• Market Restraints
  • Side effects associated with the use of non-steroidal anti-inflammatory drugs
• Market Opportunities
  • Quick authority approvals by the governments and increase in government initiatives
  • Emerging technology, research and development activities, and launch of novel drugs
• Market Challenges
  • Failure of drug during the clinical trial

Porter's Five Forces: A Strategic Tool for Navigating the Non-steroidal Anti-inflammatory Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-steroidal Anti-inflammatory Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-steroidal Anti-inflammatory Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-steroidal Anti-inflammatory Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-steroidal Anti-inflammatory Drugs Market

A detailed market share analysis in the Non-steroidal Anti-inflammatory Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-steroidal Anti-inflammatory Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-steroidal Anti-inflammatory Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-steroidal Anti-inflammatory Drugs Market

A strategic analysis of the Non-steroidal Anti-inflammatory Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-steroidal Anti-inflammatory Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Assertio Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Iroko Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Perrigo Company PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Non-steroidal Anti-inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Indication, market is studied across Arthritis, Migraine, and Ophthalmic Diseases.
• Based on Drugs, market is studied across Over-the-counter Drugs and Prescription. The Over-the-counter Drugs is further studied across Aspirin (Bufferin, Bayer, & Excedrin), Ibuprofen (Advil, Motrin, Nuprin), Ketoprofen (Actron, Orudis), and Naproxen (Aleve). The Prescription is further studied across Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, and Voltaren.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in chronic pain cases and surge in inflammation cases
    • 5.1.1.2. Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
    • 5.1.1.3. Increasing preference of people for nsaids over opioids
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with the use of non-steroidal anti-inflammatory drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Quick authority approvals by the governments and increase in government initiatives
    • 5.1.3.2. Emerging technology, research and development activities, and launch of novel drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Failure of drug during the clinical trial
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication

• 6.1. Introduction
• 6.2. Arthritis
• 6.3. Migraine
• 6.4. Ophthalmic Diseases

7. Non-steroidal Anti-inflammatory Drugs Market, by Drugs

• 7.1. Introduction
• 7.2. Over-the-counter Drugs
  • 7.2.1. Aspirin (Bufferin, Bayer, & Excedrin)
  • 7.2.2. Ibuprofen (Advil, Motrin, Nuprin)
  • 7.2.3. Ketoprofen (Actron, Orudis)
  • 7.2.4. Naproxen (Aleve)
• 7.3. Prescription
  • 7.3.1. Daypro
  • 7.3.2. Indocin
  • 7.3.3. Lodine
  • 7.3.4. Naprosyn
  • 7.3.5. Relafen
  • 7.3.6. Vimovo
  • 7.3.7. Voltaren

8. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Drug Store
• 9.3. Hospital Pharmacy
• 9.4. Online Pharmacy
• 9.5. Retail Pharmacy

10. Americas Non-steroidal Anti-inflammatory Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Apotex Inc.
• 2. Assertio Therapeutics, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Boehringer Ingelheim International GmbH
• 6. Eli Lilly and Company
• 7. GlaxoSmithKline PLC
• 8. Iroko Pharmaceuticals Inc.
• 9. Johnson & Johnson Services, Inc.
• 10. Merck & Co., Inc.
• 11. Perrigo Company PLC
• 12. Pfizer Inc.
• 13. Reckitt Benckiser Group PLC
• 14. Sanofi S.A.
• 15. Teva Pharmaceutical Industries Ltd.